JPWO2019136368A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019136368A5 JPWO2019136368A5 JP2020537565A JP2020537565A JPWO2019136368A5 JP WO2019136368 A5 JPWO2019136368 A5 JP WO2019136368A5 JP 2020537565 A JP2020537565 A JP 2020537565A JP 2020537565 A JP2020537565 A JP 2020537565A JP WO2019136368 A5 JPWO2019136368 A5 JP WO2019136368A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pharmaceutical composition
- cycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 10
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 10
- 201000005962 mycosis fungoides Diseases 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 102000009410 Chemokine receptor Human genes 0.000 claims 7
- 108050000299 Chemokine receptor Proteins 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 229940126214 compound 3 Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 229940125904 compound 1 Drugs 0.000 claims 3
- 229940125782 compound 2 Drugs 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002523 pancreas lymphoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614923P | 2018-01-08 | 2018-01-08 | |
| US62/614,923 | 2018-01-08 | ||
| PCT/US2019/012515 WO2019136368A2 (en) | 2018-01-08 | 2019-01-07 | Methods of treating solid tumors with ccr2 antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021509678A JP2021509678A (ja) | 2021-04-01 |
| JP2021509678A5 JP2021509678A5 (https=) | 2022-01-18 |
| JPWO2019136368A5 true JPWO2019136368A5 (https=) | 2022-01-18 |
| JP7442141B2 JP7442141B2 (ja) | 2024-03-04 |
Family
ID=67139234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537565A Active JP7442141B2 (ja) | 2018-01-08 | 2019-01-07 | Ｃｃｒ２アンタゴニストによる固形腫瘍の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11154556B2 (https=) |
| EP (1) | EP3737367B1 (https=) |
| JP (1) | JP7442141B2 (https=) |
| CN (1) | CN112105353B (https=) |
| AU (1) | AU2019205784B2 (https=) |
| CA (1) | CA3087765A1 (https=) |
| ES (1) | ES2991280T3 (https=) |
| IL (1) | IL275898B2 (https=) |
| MA (1) | MA50423A (https=) |
| TW (1) | TWI882953B (https=) |
| WO (1) | WO2019136368A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2904252T3 (es) | 2015-05-21 | 2022-04-04 | Chemocentryx Inc | Moduladores de CCR2 |
| CN118267479A (zh) | 2017-09-25 | 2024-07-02 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| US20190275015A1 (en) * | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| CN111334575A (zh) * | 2020-02-18 | 2020-06-26 | 至本医疗科技（上海）有限公司 | Notch家族基因变异在预测实体瘤患者对免疫检查点抑制剂疗法敏感性中的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR034257A1 (es) | 2000-06-30 | 2004-02-18 | Du Pont Pharm Co | Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas |
| EP1318811B1 (en) | 2000-08-17 | 2006-08-30 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| KR20040013090A (ko) | 2001-07-02 | 2004-02-11 | 아스트라제네카 아베 | 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체 |
| EP1501507B1 (en) | 2002-04-29 | 2008-05-28 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| US20060030582A1 (en) | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| JP4459807B2 (ja) | 2002-04-29 | 2010-04-28 | メルク エンド カムパニー インコーポレーテッド | テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤 |
| WO2004041777A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Heteroarylpiperidine modulators of chemokine receptor activity |
| US7557120B2 (en) | 2003-02-24 | 2009-07-07 | Merck & Co., Inc. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| WO2004082682A1 (en) | 2003-03-18 | 2004-09-30 | Merck & Co. Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
| KR20060003353A (ko) | 2003-04-15 | 2006-01-10 | 머크 앤드 캄파니 인코포레이티드 | 케모킨 수용체의벤족사지닐-아미도사이클로펜틸-헤테로사이클릭 조절제 |
| CA2521625A1 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
| AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
| ATE517622T1 (de) | 2003-10-27 | 2011-08-15 | Merck Sharp & Dohme | Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten |
| EP1701724A4 (en) | 2004-01-02 | 2007-11-14 | Merck & Co Inc | ALKYLAMINO, ARYLAMINO AND SULFONAMIDOCYCLOPENTYLAMIDE MODULATORS OF THE ACTIVITY OF CHEMOKIN RECEPTORS |
| CA2555073A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Amino heterocyclic modulators of chemokine receptor activity |
| JP2007537264A (ja) | 2004-05-11 | 2007-12-20 | インサイト コーポレイション | ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド |
| UY29219A1 (es) | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
| CN101098700A (zh) | 2005-01-06 | 2008-01-02 | 默克公司 | 治疗炎性疾病的药物组合疗法和药用组合物 |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PL2175859T3 (pl) | 2007-07-12 | 2012-09-28 | Chemocentryx Inc | Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| WO2010068663A1 (en) | 2008-12-10 | 2010-06-17 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| MX2011010919A (es) | 2009-04-16 | 2011-11-02 | Janssen Pharmaceutica Nv | Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano. |
| CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
| ES2674275T3 (es) | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| US9040526B2 (en) | 2010-02-09 | 2015-05-26 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| TW201204717A (en) | 2010-06-17 | 2012-02-01 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| AU2012226890B2 (en) | 2011-03-10 | 2016-10-06 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| HK1208236A1 (en) * | 2012-06-22 | 2016-02-26 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CA2915838C (en) * | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| CA2920113A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| JP6417419B2 (ja) | 2013-09-04 | 2018-11-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 免疫調節剤として有用な化合物 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| TN2017000084A1 (en) | 2014-09-11 | 2018-07-04 | Bristol Myers Squibb Co | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| ES2904252T3 (es) | 2015-05-21 | 2022-04-04 | Chemocentryx Inc | Moduladores de CCR2 |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| WO2018005374A1 (en) * | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN118267479A (zh) | 2017-09-25 | 2024-07-02 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
-
2019
- 2019-01-07 IL IL275898A patent/IL275898B2/en unknown
- 2019-01-07 WO PCT/US2019/012515 patent/WO2019136368A2/en not_active Ceased
- 2019-01-07 CA CA3087765A patent/CA3087765A1/en active Pending
- 2019-01-07 AU AU2019205784A patent/AU2019205784B2/en active Active
- 2019-01-07 US US16/241,391 patent/US11154556B2/en active Active
- 2019-01-07 ES ES19735699T patent/ES2991280T3/es active Active
- 2019-01-07 CN CN201980017482.2A patent/CN112105353B/zh active Active
- 2019-01-07 JP JP2020537565A patent/JP7442141B2/ja active Active
- 2019-01-07 EP EP19735699.1A patent/EP3737367B1/en active Active
- 2019-01-07 MA MA050423A patent/MA50423A/fr unknown
- 2019-01-08 TW TW108100692A patent/TWI882953B/zh active
-
2021
- 2021-09-22 US US17/481,829 patent/US20220241290A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509678A5 (https=) | ||
| RU2018129308A (ru) | Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их | |
| JP2020535144A5 (https=) | ||
| JP2021510376A5 (https=) | ||
| JP2001526269A5 (https=) | ||
| US20230183262A1 (en) | Substituted eneoxindoles and uses thereof | |
| JP2015520143A5 (https=) | ||
| JP2020504715A5 (https=) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2001526222A5 (https=) | ||
| HRP20211164T1 (hr) | Derivati hemiasterlina za konjugaciju i terapiju | |
| JP2019511565A5 (https=) | ||
| JP2016526540A5 (https=) | ||
| JPWO2020093061A5 (https=) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2021501756A5 (https=) | ||
| JP2009543771A5 (https=) | ||
| JP2020537645A5 (https=) | ||
| RU2016129110A (ru) | Производные пиперазина, характеризующиеся мультимодальной активностью в отношении боли | |
| CN114516857A (zh) | Hpk1抑制剂及其用途 | |
| JPWO2019136368A5 (https=) | ||
| WO2017106568A1 (en) | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer | |
| JPWO2021061870A5 (https=) | ||
| IL273387B2 (en) | Thylanstatin analogs | |
| US20210379106A1 (en) | Oxabicycloheptanes for enhancing car t cell function |